6CM
CLDX icon

683 Capital Management’s Celldex Therapeutics CLDX Stock Holding History

683 Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,727
Closed -$363K – 187
2020
Q4 		$363K Buy
+20,727
New +$373K 0.02% 152

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

683 Capital Management's CLDX Position: Q1 2021 in Review

683 Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 20,727 shares — an estimated $363K sold.

683 Capital Management first reported a position in CLDX in Q4 2020 and held it in 1 quarter. The position peaked at $363K in Q4 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

  • 683 Capital Management reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
  • 683 Capital Management sold 20,727 Celldex Therapeutics shares in Q1 2021, an estimated $363K.
  • 683 Capital Management first reported a position in Celldex Therapeutics in Q4 2020 and held it in 1 quarter.
  • 683 Capital Management's Celldex Therapeutics position peaked at $363K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.